SCHEMBL27409381

SCHEMBL27409381

COc1ccc(-c2nccs2)cc1N

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMPD3 Q9NY59 1/20 0.56
LOXL2 Q9Y4K0 1/20 0.46
ECE1 P42892 1/20 0.45
ALDH1A1 P00352 3/20 0.44
PTGDR2 Q9Y5Y4 1/20 0.44
HCRTR1 O43613 1/20 0.43
HCRTR2 O43614 1/20 0.43
PDPK1 O15530 1/20 0.43
CYP3A4 P08684 1/20 0.43
HDAC2 Q92769 1/20 0.43
TUBB4A P04350 1/20 0.43
TUBB P07437 1/20 0.43
TUBA3C P0DPH7 1/20 0.43
TUBA1B P68363 1/20 0.43
TUBA4A P68366 1/20 0.43
TUBB4B P68371 1/20 0.43
TUBB3 Q13509 1/20 0.43
TUBB2A Q13885 1/20 0.43
TUBB8 Q3ZCM7 1/20 0.43
TUBA3E Q6PEY2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22040486 0.88 SMPD3 (0.60) SMPD3LOXL2ECE1ALDH1A1PTGDR2
SCHEMBL27409981 0.85 POLB (0.50) SMPD3LOXL2ALDH1A1PTGDR2PDPK1
SCHEMBL8234511 0.82 PTGDR2 (0.52) SMPD3LOXL2ECE1PTGDR2HCRTR1
SCHEMBL22000048 0.81 SMPD3 (0.56) SMPD3LOXL2ECE1PTGDR2PDPK1
SCHEMBL8078437 0.81 SMPD3 (0.52) SMPD3LOXL2ECE1ALDH1A1PTGDR2
SCHEMBL1068648 0.80 LOXL2 (0.55) SMPD3LOXL2ALDH1A1PTGDR2PDPK1
SCHEMBL3247666 0.79 LOXL2 (0.50) SMPD3LOXL2ALDH1A1PDPK1HDAC2
SCHEMBL15010747 0.78 SMPD3 (0.60) SMPD3LOXL2ECE1PTGDR2HCRTR1
SCHEMBL29291643 0.78 SMPD3 (0.52) SMPD3ECE1ALDH1A1PTGDR2PDPK1
SCHEMBL7054724 0.78 SMPD3 (0.52) SMPD3ECE1ALDH1A1PTGDR2PDPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260108527-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS INC (US) 2026-04-23 US disclosed
EP-4598912-A1 POLO LIKE KINASE 4 INHIBITORS Oric Pharmaceuticals, Inc. (US) 2025-08-13 EP disclosed
WO-2024076891-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. (US) 2024-04-11 WO disclosed
WO-2024076891-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. (US) 2024-04-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260108527-A1 POLO LIKE KINASE 4 INHIBITORS PLK4, PLK2, PLK3 SMPD3 1955/4885LOXL2 1257/4885ECE1 4538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.